TP53 and neoplasm: Patients, in whom high tumor tissue immunoreactivity towards OPN, survivin, p53 and cyclin D1, or just three of the four markers were stated at diagnosis, responded significantly worse to CHT than patients, who expressed no more than two of these markers (p = 0.009).